Primary fibroblasts derived from sporadic amyotrophic lateral sclerosis patients do not show ALS cytological lesions

Abstract Objective: Sporadic amyotrophic lateral sclerosis (sALS) is a fatal neurodegenerative disorder affecting upper and lower motor neurons. In view of the heterogeneous presentation of the disease, one of the current challenges is to identify diagnostic and prognostic markers in order to diagnose sALS at early stage and to stratify patients in trials. In this study, we sought to identify cytological hallmarks of sALS in patient-derived fibroblasts with the aim of finding new clinical-related markers of the disease. Methods: Primary fibroblasts were prospectively collected from patients affected with classical, rapid, and slow forms of sALS. TDP-43 localization, cytoskeleton distribution, mitochondrial network architecture, and stress granules formation were analyzed using 3D fluorescence microscopy and new super-resolution imaging. Intracellular reactive oxygen species (ROS) production was assessed using live imaging techniques. Results: Six sALS patients (two classical, two rapid, and two slow) and four age-matched controls were included. No difference in fibroblasts cell growth, morphology, and distribution was noticed. The analysis of TDP-43 did not reveal any mislocalization nor aggregation of the protein. The cytoskeleton was harmoniously distributed among the cells, without any inclusion noticed, and no difference was observed regarding the mitochondrial network architecture. Basal ROS production and response to induced stress were similar among patient and control fibroblasts. Conclusions: ALS cytological lesions are absent in patient-derived fibroblasts and thus cannot contribute as diagnostic nor prognostic markers of the disease.

[1]  Chadwick M. Hales,et al.  Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patients , 2017, Molecular Neurodegeneration.

[2]  J. Cassereau,et al.  Neuronal Intermediate Filaments in Amyotrophic Lateral Sclerosis , 2016 .

[3]  Hu Li,et al.  The Inhibition of TDP-43 Mitochondrial Localization Blocks Its Neuronal Toxicity , 2016, Nature Medicine.

[4]  V. Tiranti,et al.  Gene-specific mitochondria dysfunctions in human TARDBP and C9ORF72 fibroblasts , 2016, Acta neuropathologica communications.

[5]  U. Jinwal,et al.  Identification of Apo B48 and other novel biomarkers in amyotrophic lateral sclerosis patient fibroblasts. , 2016, Biomarkers in medicine.

[6]  R. Goldman,et al.  Abnormal intermediate filament organization alters mitochondrial motility in giant axonal neuropathy fibroblasts , 2016, Molecular biology of the cell.

[7]  A. Grierson,et al.  Altered age-related changes in bioenergetic properties and mitochondrial morphology in fibroblasts from sporadic amyotrophic lateral sclerosis patients , 2015, Neurobiology of Aging.

[8]  P. Rossini,et al.  Primary fibroblasts cultures reveal TDP-43 abnormalities in amyotrophic lateral sclerosis patients with and without SOD1 mutations , 2015, Neurobiology of Aging.

[9]  Yong Yu,et al.  U1 snRNP is mislocalized in ALS patient fibroblasts bearing NLS mutations in FUS and is required for motor neuron outgrowth in zebrafish , 2015, Nucleic acids research.

[10]  J. Bouchard,et al.  Early detection of structural abnormalities and cytoplasmic accumulation of TDP-43 in tissue-engineered skins derived from ALS patients , 2015, Acta neuropathologica communications.

[11]  R. Raman,et al.  Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions , 2015, Neuropathology and applied neurobiology.

[12]  W. Robberecht,et al.  The phenotypic variability of amyotrophic lateral sclerosis , 2014, Nature Reviews Neurology.

[13]  H. Mitsumoto,et al.  Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? , 2014, The Lancet Neurology.

[14]  C. Gennings,et al.  Bioenergetic markers in skin fibroblasts of sporadic amyotrophic lateral sclerosis and progressive lateral sclerosis patients , 2014, Annals of neurology.

[15]  K. Eggan,et al.  FUS is sequestered in nuclear aggregates in ALS patient fibroblasts , 2014, Molecular biology of the cell.

[16]  E. Génin,et al.  A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. , 2014, Brain : a journal of neurology.

[17]  Pamela J. Shaw,et al.  Superoxide dismutase 1 mutation in a cellular model of amyotrophic lateral sclerosis shifts energy generation from oxidative phosphorylation to glycolysis , 2014, Neurobiology of Aging.

[18]  S. Ono,et al.  Abundant FUS‐immunoreactive pathology in the skin of sporadic amyotrophic lateral sclerosis , 2013, Acta neurologica Scandinavica.

[19]  R. Martinez,et al.  A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells , 2013, Molecular and Cellular Neuroscience.

[20]  Nick C Fox,et al.  Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels , 2013, Neuron.

[21]  David Heckerman,et al.  A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.

[22]  J. Haines,et al.  Mutations in UBQLN2 cause dominant X-linked juvenile and adult onset ALS and ALS/dementia , 2011, Nature.

[23]  O. Hardiman,et al.  Amyotrophic lateral sclerosis , 2011, The Lancet.

[24]  S. Ono,et al.  An immunohistochemical study of ubiquitin in the skin of sporadic amyotrophic lateral sclerosis , 2010, Journal of the Neurological Sciences.

[25]  H. Ishikawa,et al.  Increased expression of TDP‐43 in the skin of amyotrophic lateral sclerosis , 2010, Acta neurologica Scandinavica.

[26]  H. Lublin,et al.  Evaluation of a multifaceted intervention to limit excessive antipsychotic co‐prescribing in schizophrenia out‐patients , 2010, Acta psychiatrica Scandinavica.

[27]  E. Calabrese,et al.  Lack of Evidence for Oxidative Stress in Sporadic Amyotrophic Lateral Sclerosis Fibroblasts , 2008, Neurodegenerative Diseases.

[28]  J. Trojanowski,et al.  Pathological TDP‐43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations , 2007, Annals of neurology.

[29]  M. Iwata,et al.  Mitochondrial Alterations in the Spinal Cord of Patients With Sporadic Amyotrophic Lateral Sclerosis , 2007, Journal of neuropathology and experimental neurology.

[30]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[31]  E. Schon,et al.  Mitochondrial DNA and respiratory chain function in spinal cords of ALS patients , 2002, Journal of neurochemistry.

[32]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[33]  Robert H. Brown,et al.  Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis , 1997, Journal of neurochemistry.

[34]  Robert H. Brown,et al.  Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis , 1997, Annals of neurology.

[35]  R. Wanders,et al.  Evidence against increased oxidative stress in fibroblasts from patients with non-superoxide-dismutase-1 mutant familial amyotrophic lateral sclerosis , 1996, Journal of the Neurological Sciences.

[36]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[37]  D. Perl,et al.  Accumulation of Phosphorylated Neurofilaments in Anterior Horn Motoneurons of Amyotrophic Lateral Sclerosis Patients , 1988, Journal of neuropathology and experimental neurology.

[38]  C. Carcassi,et al.  Reduced stress granule formation and cell death in fibroblasts with the A382T mutation of TARDBP gene: evidence for loss of TDP-43 nuclear function. , 2016, Human molecular genetics.

[39]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[40]  R. Miller,et al.  Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). , 2003, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.